Objective:Epidermal growth factor receptor(EGFR)mutation,particularly E746_A750del and L858R,is thought to be associated with clinical outcomes of patients with non-small cell lung cancer(NSCLC) receiving TKIs treatment,suggesting that EGFR mutation test may play an important role in clinical decision. So,establishment of a rapid,simple and cost-effectiveness EGFR mutation test method can effectively relieve the financial burden of patients. Methods:We established a rapid and sensitive assay for detecting EGFR mutation by asymmetrical PCR and Junction Probe (APCR-JP). In this study,37 NSCLC tissue samples were detected by APCR-JP assay. Results:Seventeen samples (45.9%) carried 19del mutation and 8 samples (21%) had L858R mutation,which are consistent with the results of direct sequencing. Conclusion:These results suggest that APCR-JP could be used in EGFR mutation detection and provide imformation for clinical decision.